

November 6, 2014

Matrix, Company Name 3 - D Ltd. 3-2-4, Kojimachi, Chiyoda, Tokyo Address President Kentaro Takamura Code Number 7777 C on tact Director Tomoyuki Arai \mathbf{T} +81 3 (3511)3440 \mathbf{E} \mathbf{L}

<u>Absorbable Hemostat "PuraStat®"</u> <u>Implementation of clinical use in Hong Kong</u>

The 3-D Matrix group has been working towards starting clinical use of absorbable hemostat "PuraStat®" since obtaining CE marking for the product on January 14, 2014. The company hereby announces that on Oct 30, 2014, clinical use of the product has been conducted in Pamela Youde Nethersole Eastern Hospital in Hong Kong.

Chung Ngai TANG, M.D. who is Chief of Service, Department of Surgery and also Director of Minimal Access Surgery Training Centre of Pamela Youde Nethersole Eastern Hospital, conducted the clinical use to control bleeding during a surgical procedure. Pamela Youde Nethersole Eastern Hospital is a flagship hospital conducting more than 5,000 surgery cases annually.

With the commencement of clinical use, the company aims to further promote clinical use of PuraStat® in our Hong Kong markets, and expand the distribution of the product through an exclusive agreement with a marketing partner.

This announcement does not influence the earning forecast of the company at this moment.